IceCure's ProSense® Cryoablation featured in 4 breast cancer studies with 263 patients presented at RSNA 2025.

Unusual Whales
2025.12.10 13:33
During a conference in CAESAREA, Israel on December 10, 2025, abstracts of 3 studies were presented involving a total of 263 patients. These studies contribute to the increasing evidence base supporting the wider use of ProSense®. IceCure Medical Ltd. (NASDAQ: ICCM) shared this information, highlighting the positive results across diverse patient populations.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer